DrugPatentWatch Database Preview

Details for Patent: 8,155,737

« Back to Dashboard

Which drugs does patent 8,155,737 protect, and when does it expire?

Patent 8,155,737 protects ZECUITY and is included in one NDA.

This patent has seventeen patent family members in eleven countries.

Summary for Patent: 8,155,737

Title:	Pharmacokinetics of iontophoretic sumatriptan administration
Abstract:	Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.
Inventor(s):	Sebree; Terri B. (Gladwyne, PA), Pierce; Mark (Essex, CT), O'Neill; Carol (Conshohocken, PA)
Assignee:	NuPathe, Inc. (Conshohocken, PA)
Application Number:	12/142,604
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,155,737
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,155,737

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	ZECUITY	sumatriptan succinate	SYSTEM;IONTOPHORESIS	202278-001	Jan 17, 2013		DISCN	Yes	No						METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

International Family Members for US Patent 8,155,737

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2008358027
Australia	2015238858
Canada	2727927
Eurasian Patent Organization	025505
Eurasian Patent Organization	201100056